Clinical trials: 5-FU, completed
Rectal Cancer, Colon Cancer
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
- Trial name
- NCT00101894
- Testing
- FOLFOX-4, AMG 706, Panitumumab (Part 1a only)
- Volunteers
- 119 people
- Sponsor
- Amgen
Esophageal Cancer, Adenocarcinoma, Esophageal
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown. Although an operation to remove the esophagus is the most common treatment, previous studies have shown that patients live longer when…
- Conditions
- Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
- Trial name
- POWERRANGER (NCT01404156)
- Testing
- (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Dr. Gordon Buduhan
Metastatic Colorectal Cancer
Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea
Irinotecan (7-ethyl-10- {4(-1-piperidino)-1-piperidino} carbonyloxy camptothecin) is a semisynthetic camptothecin derivative introduced in the 1980's.
- Trial name
- NCT00255229
- Testing
- Glutamine
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
This is an open randomized phase III study. The primary objective of this study is to compare FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated according to the patients surface area or…
- Trial name
- NCT03888677
- Testing
- 5-FU, epirubicin and cyclophosphamide
- Volunteers
- 1,535 people
- Sponsor
- Henrik Lindman
Metastatic Colorectal Cancer
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
- Trial name
- NCT00252564
- Testing
- Bevacizumab, Oxaliplatin, Leucovorin
- Where
- 82 sites in United States
- Volunteers
- 247 people
- Sponsor
- US Oncology Research
Biliary Tract Cancer
Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
The main objective of the study is to establish if patients with advanced bile duct cancer, who have already received a line of treatment for their disease, will receive any associated benefits from the combination of mFOLFOX6…
- Trial name
- COMBATBIL (NCT05052099)
- Testing
- mFOLFOX6, Atezolizumab and Bevacizumab
- Where
- 2 sites in Germany, Spain
- Volunteers
- 20 people
- Sponsor
- University Hospital, Essen
Metastatic Esophageal Cancer, Gastroesophageal Cancer
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
- Conditions
- Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
- Trial name
- NCT01715233
- Testing
- Docetaxel, Leucovorin, Fluorouracil
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV Infections, Cervix, Dysplasia
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women
To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis in HIV-infected women who have received standard ablative therapy (surgery) for high-grade cervical dysplasia (pre-cancer of the…
- Trial name
- NCT00000758
- Testing
- Fluorouracil
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 158 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gastric Cancer Stage IV, Peritoneal Carcinomatosis
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
- Trial name
- IPLUS (NCT03618758)
- Testing
- Paclitaxel, mFOLFOX6 regimen
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Seoul National University Bundang Hospital
Esophageal Cancer
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal cancer is a highly aggressive tumor. Treatment options are various and range from chemotherapy to radiotherapy and several surgical techniques. Nevertheless, the overall survival rates for this disease remain poor.
- Trial name
- NCT01787006
- Testing
- Cetuximab, Cisplatin, 5-FU, Radiotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- University Hospital Schleswig-Holstein
Breast Cancer, Chemotherapy, Adjuvant
Adjuvant FEC Versus EP in Breast Cancer (MIG5)
In this multicenter, randomized phase III trial, node positive early breast cancer patients are randomly assigned to receive either 6 cycles of FEC (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, on…
- Trial name
- MIG5 (NCT02450058)
- Testing
- 5-fluorouracil, epirubicin, cyclophosphamide
- Where
- 8 sites in Italy
- Volunteers
- 1,055 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined.
- Trial name
- NCT05249426
- Testing
- BI 765063, Ezabenlimab, BI 836880
- Where
- 25 sites in United States, France and 9 more
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Malignant Neoplasm of Stomach Stage IV
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.
- Trial name
- NCT02845908
- Testing
- POF, FOLFOX, FOLFOX plus PAC(ip)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Cancer Hospital
BRCA Gene Rearrangement
BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer
The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis according to BRCA loss.
- Trial name
- NCT03838406
- Testing
- BRCA 1, Chemotherapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Chung-Ang University
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of bortezomib when given together with fluorouracil and leucovorin calcium in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Trial name
- NCT00007878
- Testing
- bortezomib, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell of Head and Neck
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Part 1 of this study will establish a recommended Phase II (RPII) dose for the triplet combination of NC-6004 plus 5-Fluorouracil (5-FU) and cetuximab.
- Trial name
- NCT03109158
- Testing
- NC-6004, Cetuximab, 5-FU
- Where
- 20 sites in United States, Bulgaria and 2 more
- Volunteers
- 1 people
- Sponsor
- NanoCarrier Co., Ltd.
Advanced Colorectal Cancer, Adenocarcinoma of the Colon
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
- Conditions
- Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT00707889
- Testing
- ABT-869, bevacizumab, oxaliplatin
- Where
- 46 sites in United States, Australia and 12 more
- Volunteers
- 159 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
- Trial name
- NCT02625610
- Testing
- Avelumab, Oxaliplatin, 5-Fluorouracil
- Where
- 200 sites in United States, Australia and 15 more
- Volunteers
- 499 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.